98 related articles for article (PubMed ID: 23217386)
1. MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation.
Liu SY; Liang Y; Lin TX; Su F; Liang WW; Uwe H; Li Y
Chin Med J (Engl); 2012 Dec; 125(23):4197-201. PubMed ID: 23217386
[TBL] [Abstract][Full Text] [Related]
2. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt.
Liu S; Li Y; Lin T; Fan X; Liang Y; Heemann U
Diabetes Res Clin Pract; 2011 Feb; 91(2):177-82. PubMed ID: 21129803
[TBL] [Abstract][Full Text] [Related]
3. MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression.
Huth HW; Albarnaz JD; Torres AA; Bonjardim CA; Ropert C
Cell Signal; 2016 Sep; 28(9):1283-1291. PubMed ID: 27181679
[TBL] [Abstract][Full Text] [Related]
4. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of MEK inhibitors on rat neural stem cell differentiation: Repressive roles of MEK2 in neurogenesis and induction of astrocytogenesis by PD98059.
Lee HR; Lee J; Kim HJ
Pharmacol Res; 2019 Nov; 149():104466. PubMed ID: 31562895
[TBL] [Abstract][Full Text] [Related]
6. MEK1 and MEK2 isoforms regulate distinct functions in pancreatic cancer cells.
Zhou L; Tan X; Kamohara H; Wang W; Wang B; Liu J; Egami H; Baba H; Dai X
Oncol Rep; 2010 Jul; 24(1):251-5. PubMed ID: 20514469
[TBL] [Abstract][Full Text] [Related]
7. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
8. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Zhang YX; Kong CZ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
[TBL] [Abstract][Full Text] [Related]
9. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.
Voisin L; Julien C; Duhamel S; Gopalbhai K; Claveau I; Saba-El-Leil MK; Rodrigue-Gervais IG; Gaboury L; Lamarre D; Basik M; Meloche S
BMC Cancer; 2008 Nov; 8():337. PubMed ID: 19014680
[TBL] [Abstract][Full Text] [Related]
10. The Leydig cell MEK/ERK pathway is critical for maintaining a functional population of adult Leydig cells and for fertility.
Yamashita S; Tai P; Charron J; Ko C; Ascoli M
Mol Endocrinol; 2011 Jul; 25(7):1211-22. PubMed ID: 21527500
[TBL] [Abstract][Full Text] [Related]
11. [Activation of HIF-1 by bFGF in breast cancer: role of PI-3K and MEK1/ERK pathways].
Shi YH; Wang YX; You JF; Heng WJ; Zhong HH; Fang WG
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1899-903. PubMed ID: 15631803
[TBL] [Abstract][Full Text] [Related]
12. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
[TBL] [Abstract][Full Text] [Related]
13. Selective transcriptional down-regulation of human rhinovirus-induced production of CXCL10 from airway epithelial cells via the MEK1 pathway.
Zaheer RS; Koetzler R; Holden NS; Wiehler S; Proud D
J Immunol; 2009 Apr; 182(8):4854-64. PubMed ID: 19342664
[TBL] [Abstract][Full Text] [Related]
14. MEK1/2 overactivation can promote growth arrest by mediating ERK1/2-dependent phosphorylation of p70S6K.
Guégan JP; Ezan F; Gailhouste L; Langouët S; Baffet G
J Cell Physiol; 2014 Jul; 229(7):903-15. PubMed ID: 24501087
[TBL] [Abstract][Full Text] [Related]
15. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
Lee SY; Shin SJ; Kim HS
Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
[TBL] [Abstract][Full Text] [Related]
16. Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression.
Chen T; Yang M; Yu Z; Tang S; Wang C; Zhu X; Guo J; Li N; Zhang W; Hou J; Liu H; Han C; Liu Q; Gu Y; Qian C; Wan T; Cui L; Zhu M; Zheng W; Cao X
Cancer Cell; 2014 May; 25(5):682-96. PubMed ID: 24746703
[TBL] [Abstract][Full Text] [Related]
17. Towards the development of chromone-based MEK1/2 modulators.
Redwan IN; Dyrager C; Solano C; Fernández de Trocóniz G; Voisin L; Bliman D; Meloche S; Grøtli M
Eur J Med Chem; 2014 Oct; 85():127-38. PubMed ID: 25078316
[TBL] [Abstract][Full Text] [Related]
18. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
Senawong T; Phuchareon J; Ohara O; McCormick F; Rauen KA; Tetsu O
Hum Mol Genet; 2008 Feb; 17(3):419-30. PubMed ID: 17981815
[TBL] [Abstract][Full Text] [Related]
19. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
Caunt CJ; Sale MJ; Smith PD; Cook SJ
Nat Rev Cancer; 2015 Oct; 15(10):577-92. PubMed ID: 26399658
[TBL] [Abstract][Full Text] [Related]
20. Preventing MEK1 activation influences the responses of human osteosarcoma cells to bone morphogenetic proteins 2 and 9.
Park H; Drevelle O; Daviau A; Senta H; Bergeron E; Faucheux N
Anticancer Drugs; 2013 Mar; 24(3):278-90. PubMed ID: 23262982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
